Apimeds Pharmaceuticals US, Inc.

AMEX: APUS
NYSE American
Healthcare Biotechnology
Global Rank
#36073
Country Rank
#4677
Market Cap
21.3 M
Price
2.04
Change (%)
0.49%
Volume
25,279

Apimeds Pharmaceuticals US, Inc.'s latest marketcap:

21.3 M

As of 07/29/2025, Apimeds Pharmaceuticals US, Inc.'s market capitalization has reached $21.3 M. According to our data, Apimeds Pharmaceuticals US, Inc. is the 36073th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 21.3 M
Revenue (ttm) 0
Net Income (ttm) -1,495,914
Shares Out 11.58 M
EPS (ttm) -0.19
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 08/22/2025
Market Cap Chart
Data Updated: 07/29/2025

Apimeds Pharmaceuticals US, Inc.'s yearly market capitalization.

Date Market Cap($) Change (%) Global Rank
07/29/2025 $21.3 M 36073

Company Profile

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.

It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.

The company was incorporated in 2020 and is based in Hopewell, New Jersey.

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.